February 05, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub.: Outcome of Inspection by National Centre for Public Health and Pharmacy, Hungary at manufacturing facility of Panacea Biotec Pharma Limited at Baddi, Himachal Pradesh

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform that the National Centre for Public Health and Pharmacy, Hungary ("NCPHP") has conducted an inspection of the manufacturing facility of the Company's wholly owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") at Baddi, Himachal Pradesh, India ("Baddi Facility") from January 26, 2026 to January 31, 2026.

Following the inspection, NCPHP issued a "Statement of non-compliance with Good Manufacturing Practice" ("GMP") dated February 03, 2026, received by PBPL on February 04, 2026, wherein NCPHP has considered that the Baddi Facility does not comply with the GMP requirements as laid down in Directive (EU) 2017/1572, resulting in revocation of all valid GMP certificates issued by NCPHP ("GMP Certificates"). NCPHP has proposed halting of supplies of non-vital products, except those supplying patients being on treatment with oncology products.

However, officials of NCPHP did not observe any behaviour or manufacturing process that would pose risk to the quality of products already released.

This is to clarify that PBPL is not supplying any oncology related products in European Union markets.

During FY 2024-25, PBPL's revenue to European Union markets contributes around 0.32% of the total consolidated net revenues of Panacea Biotec Limited. PBPL's export revenue in European Union markets represents products that are vital for patients undergoing long term immunosuppression or anti-viral therapy. Any interruption of supply could pose a significant clinical risk to patients. This aspect is being taken into account in the ongoing risk-benefit assessment in close coordination with the relevant regulatory agencies.

We are committed to maintaining the highest standards of quality and compliance. We are in the process of implementing comprehensive corrective and preventive actions (CAPA) and will request a re-inspection at the earliest possible opportunity to restore the GMP Certificates.

Thanking you,
Sincerely yours,
for **Panacea Biotec Limited**

ANKIT JAIN
Digitally signed by ANKIT JAIN
Date: 2026.02.05 14:34:56 +05'30'

Ankit Jain
General Manager – Legal & Company Secretary